Two doses of Pfizer-BioNTech’s COVID-19 vaccine appear to have given 70% protection against hospitalization in South Africa in recent weeks, a major real-world study on the potential impact of Omicron showed on Tuesday, as the country battles a spike in infections linked to the new variant.
The study released by South Africa’s largest private health insurance administrator, Discovery Health, was based on more than 211,000 positive COVID-19 test results from Nov. 15 to Dec. 7, around 78,000 of which were attributed to Omicron.
The 78,000 results are not confirmed Omicron cases, meaning the study is not able to make conclusive findings about the variant labeled “of concern” by the World Health Organization.
South African scientists have so far confirmed around 550 Omicron sequences, with the variant accounting for 78% of sequences from November, more than the previously dominant Delta variant.
Based on analysis by Discovery’s clinical research and actuarial teams, and in collaboration with South Africa’s Medical Research Council (SAMRC), the study calculated that two doses of Pfizer-BioNTech offered 70% protection against hospitalization compared with the unvaccinated during the recent surge in cases and 33% protection against infection.
It said this represents a drop from 80% protection against infection and compares with above 90% efficacy against hospital admission during South Africa’s outbreak of the Delta variant, which is the globally dominant variant and considered to be the most infectious to emerge during the pandemic.
Discovery cautioned that the study’s findings should be considered preliminary.
But Glenda Gray, SAMRC president, said it was important that the Pfizer-BioNTech vaccine appeared to be offering good protection against severe disease and hospitalization as a highly transmissible new variant circulates.
“We are extremely encouraged by the results,” she said in a statement.
The analysis also shows protection against hospital admission is maintained across all ages, in people from 18 to 79 years, with slightly lower levels of protection for the elderly.
Protection against admission is also consistent across a range of chronic illnesses including diabetes, hypertension, hypercholesterolemia, and other cardiovascular diseases.
South Africa is using the Pfizer-BioNTech and Johnson & Johnson vaccines in its COVID-19 immunization campaign, with more than 20 million Pfizer doses administered so far.